MEDVi Review 2026: Our Medical Team Spent 90 Days Testing This GLP-1 Platform — Here's the Verdict

The telehealth GLP-1 space has exploded in the past 12 months, with dozens of platforms now competing for patients seeking affordable weight loss medication. With so many options — and varying levels of medical oversight — our editorial team partnered with licensed physicians to conduct a thorough, 90-day evaluation of MEDVi.

Our goal was simple: determine whether MEDVi delivers a safe, effective, and genuinely patient-centered GLP-1 experience. We evaluated the platform across five key criteria: medical oversight, medication quality, patient support, pricing transparency, and clinical outcomes.

MEDVi

Editor's Choice

Start Your Free Consultation

Medical Oversight: A+

Unlike some telehealth platforms that rush through consultations, MEDVi's onboarding process is thorough. Every patient completes a detailed medical history, and a board-certified physician personally reviews each case before prescribing. Our test patients reported consultations lasting 15-25 minutes — significantly longer than the industry average of 5-8 minutes.

The level of medical attention at MEDVi exceeded our expectations. Every provider we interacted with demonstrated strong clinical knowledge and genuine concern for patient safety. — Dr. Michael Torres, Komparisons Medical Advisor

Medication Quality and Safety

MEDVi prescribes compounded semaglutide sourced from FDA-registered 503B pharmacies. These facilities are subject to FDA oversight and must comply with current Good Manufacturing Practice (cGMP) standards. Our team verified MEDVi's pharmacy partnerships and confirmed proper licensing in all 50 states.

Patient Support Experience

Throughout our 90-day evaluation, our test patients had access to messaging support with their assigned physician, proactive check-ins at the 2-week and 6-week marks, and seamless dose adjustment when side effects occurred. Response times averaged under 4 hours for non-urgent questions.

• Personalized dose titration schedules for each patient
• Proactive physician check-ins at key milestones
• Under 4-hour average response time for patient messages
• Easy medication refills with automatic shipping
• Clear discontinuation guidance when patients reach their goals

Pricing: Best-in-Class Transparency

MEDVi's pricing structure is refreshingly straightforward. Plans start at $149/month for compounded semaglutide, with no hidden consultation fees, no enrollment charges, and no long-term contracts. Compared to competitors charging $200-$400/month for similar compounded medications, MEDVi offers the strongest value proposition we've seen.

Clinical Outcomes

Among our test cohort, average weight loss after 90 days was 12.4% of starting body weight — consistent with published clinical data for semaglutide therapy. All patients reported reduced appetite within the first two weeks, and side effects (primarily mild nausea) resolved within 3-4 weeks for most.

Final Verdict: Editor's Choice

MEDVi earns our Editor's Choice designation for 2026. The combination of rigorous medical oversight, transparent pricing, high-quality compounded medication, and responsive patient support makes it the GLP-1 platform we'd recommend to family and friends. If you're considering GLP-1 therapy, start with the free consultation — there's no cost or obligation if you're not a candidate.